BioSpace News Archive

Business

Abzena Expands Leadership Team With Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer.

June 21, 2019
·
2 min read
Drug Development

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference

Achieve Life Sciences, Inc. announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019.

June 21, 2019
·
4 min read
Deals

Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline

Aurinia Pharmaceuticals Inc. reminded shareholders to vote in advance of the proxy voting deadline of 10:00 AM Mountain Time on Monday, June 24, 2019.

June 21, 2019
·
8 min read
Policy

OTC Markets Group Welcomes Eve & Co Incorporated to OTCQX

OTC Markets Group Inc. announced Eve & Co Incorporated, a company that holds cultivation and processing licenses under the Cannabis Act through its wholly owned subsidiary Natural MedCo Ltd., has qualified to trade on the OTCQX® Best Market.

June 21, 2019
·
2 min read
Drug Development

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma

Verastem, Inc. announced an oral presentation highlighting supportive Phase 1 clinical data for duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma at the 2019 International Conference on Malignant Lymphoma being held June 18-22, 2019, in Lugano, Switzerland.

June 21, 2019
·
21 min read
CannTrust Holdings Announces Voting Results from 2019 Annual and Special Meeting of Shareholders

CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX:TRST, NYSE:CTST) announces the voting results on the matters submitted to shareholders at the Company’s Annual and Special Meeting of shareholders held on June 20, 2019.

June 21, 2019
·
2 min read
FDA

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

BOTOX® is the First Neurotoxin Treatment Approved to Treat Pediatric Patients, 2 to 17 Years of Age, with Upper Limb Spasticity

June 21, 2019
·
10 min read
FDA

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3

Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia syndrome.

June 21, 2019
·
3 min read
Drug Development

Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

Epizyme, Inc. reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy.

June 21, 2019
·
9 min read
BioMidwest

Valet Health Shares Valet LaunchPad Product at Gener8tor OnRamp Healthcare Conference

On Wednesday, June 19, 2019, Valet Health, a healthcare predictive marketing company, attended the inaugural Gener8tor OnRamp Conference at Lambeau Field.

June 21, 2019
·
1 min read